These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 18492879)

  • 21. Evaluation of delayed 18F-FDG PET in differential diagnosis for malignant soft-tissue tumors.
    Hamada K; Tomita Y; Ueda T; Enomoto K; Kakunaga S; Myoui A; Higuchi I; Yoshikawa H; Hatazawa J
    Ann Nucl Med; 2006 Dec; 20(10):671-5. PubMed ID: 17385305
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Combined use of positron emission tomography with (18)F-fluorodeoxyglucose and (11)C-methionine for preoperative evaluation of gliomas].
    Yamaguchi S; Terasaka S; Kobayashi H; Narita T; Hirata K; Shiga S; Usui R; Tanaka S; Kubota K; Murata J; Asaoka K
    No Shinkei Geka; 2010 Jul; 38(7):621-8. PubMed ID: 20628188
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Breast cancer with low FDG uptake: characterization by means of dual-time point FDG-PET/CT.
    Zytoon AA; Murakami K; El-Kholy MR; El-Shorbagy E; Ebied O
    Eur J Radiol; 2009 Jun; 70(3):530-8. PubMed ID: 18395387
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnostic accuracy of
    He Q; Zhang L; Zhang B; Shi X; Yi C; Zhang X
    BMC Cancer; 2019 Apr; 19(1):332. PubMed ID: 30961564
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bilateral hilar foci on 18F-FDG PET scan in patients without lung cancer: variables associated with benign and malignant etiology.
    Karam M; Roberts-Klein S; Shet N; Chang J; Feustel P
    J Nucl Med; 2008 Sep; 49(9):1429-36. PubMed ID: 18765585
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dual time point 2-[18F]fluoro-2'-deoxyglucose positron emission tomography in chronic bacterial osteomyelitis.
    Sahlmann CO; Siefker U; Lehmann K; Meller J
    Nucl Med Commun; 2004 Aug; 25(8):819-23. PubMed ID: 15266177
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Narrow time-window dual-point 18F-FDG PET for the diagnosis of thoracic malignancy.
    Conrad GR; Sinha P
    Nucl Med Commun; 2003 Nov; 24(11):1129-37. PubMed ID: 14569166
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Voxel-based analysis of dual-time-point 18F-FDG PET images for brain tumor identification and delineation.
    Prieto E; Martí-Climent JM; Domínguez-Prado I; Garrastachu P; Díez-Valle R; Tejada S; Aristu JJ; Peñuelas I; Arbizu J
    J Nucl Med; 2011 Jun; 52(6):865-72. PubMed ID: 21571807
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overexpression of hexokinase-2 in giant cell tumor of bone is associated with false positive in bone tumor on FDG-PET/CT.
    Hoshi M; Takada J; Oebisu N; Hata K; Ieguchi M; Nakamura H
    Arch Orthop Trauma Surg; 2012 Nov; 132(11):1561-8. PubMed ID: 22825642
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Does partial volume corrected maximum SUV based on count recovery coefficient in 3D-PET/CT correlate with clinical aggressiveness of non-Hodgkin's lymphoma?
    Tsujikawa T; Otsuka H; Morita N; Saegusa H; Kobayashi M; Okazawa H; Nishitani H
    Ann Nucl Med; 2008 Jan; 22(1):23-30. PubMed ID: 18250984
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hybrid [¹⁸F]-FDG PET/MRI including non-Gaussian diffusion-weighted imaging (DWI): preliminary results in non-small cell lung cancer (NSCLC).
    Heusch P; Köhler J; Wittsack HJ; Heusner TA; Buchbender C; Poeppel TD; Nensa F; Wetter A; Gauler T; Hartung V; Lanzman RS
    Eur J Radiol; 2013 Nov; 82(11):2055-60. PubMed ID: 23830904
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of combination of contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography for evaluation of ovarian masses.
    Tsuboyama T; Tatsumi M; Onishi H; Nakamoto A; Kim T; Hori M; Sakane M; Hori Y; Morii E; Hatazawa J; Tomiyama N
    Invest Radiol; 2014 Aug; 49(8):524-31. PubMed ID: 24637584
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 18F-FET PET differentiation of ring-enhancing brain lesions.
    Floeth FW; Pauleit D; Sabel M; Reifenberger G; Stoffels G; Stummer W; Rommel F; Hamacher K; Langen KJ
    J Nucl Med; 2006 May; 47(5):776-82. PubMed ID: 16644747
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glucose-corrected standardized uptake value in the differentiation of high-grade glioma versus post-treatment changes.
    Nozawa A; Rivandi AH; Kanematsu M; Hoshi H; Piccioni D; Kesari S; Hoh CK
    Nucl Med Commun; 2015 Jun; 36(6):573-81. PubMed ID: 25714806
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FDG uptake heterogeneity evaluated by fractal analysis improves the differential diagnosis of pulmonary nodules.
    Miwa K; Inubushi M; Wagatsuma K; Nagao M; Murata T; Koyama M; Koizumi M; Sasaki M
    Eur J Radiol; 2014 Apr; 83(4):715-9. PubMed ID: 24418285
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correcting tumour SUV for enhanced bone marrow uptake: retrospective 18F-FDG PET/CT studies.
    Teo BK; Badiee S; Hadi M; Lam T; Johnson L; Seo Y; Bacharach SL; Hasegawa BH; Franc BL
    Nucl Med Commun; 2008 Apr; 29(4):359-66. PubMed ID: 18317301
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Validation of fast-RAMLA in clinical PET.
    Sato H; Cho K; Fukushima Y; Shiiba M; Hakozaki K; Kiriyama T; Sakurai M; Kanaya K; Kumita S
    Ann Nucl Med; 2008 Dec; 22(10):869-76. PubMed ID: 19142705
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of tumor volumes derived from glucose metabolic rate maps and SUV maps in dynamic 18F-FDG PET.
    Visser EP; Philippens ME; Kienhorst L; Kaanders JH; Corstens FH; de Geus-Oei LF; Oyen WJ
    J Nucl Med; 2008 Jun; 49(6):892-8. PubMed ID: 18483085
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dual-time-point [18F]-FDG PET/CT in the diagnostic evaluation of suspicious breast lesions.
    Caprio MG; Cangiano A; Imbriaco M; Soscia F; Di Martino G; Farina A; Avitabile G; Pace L; Forestieri P; Salvatore M
    Radiol Med; 2010 Mar; 115(2):215-24. PubMed ID: 20017002
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors.
    Jacobs AH; Thomas A; Kracht LW; Li H; Dittmar C; Garlip G; Galldiks N; Klein JC; Sobesky J; Hilker R; Vollmar S; Herholz K; Wienhard K; Heiss WD
    J Nucl Med; 2005 Dec; 46(12):1948-58. PubMed ID: 16330557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.